Janux Therapeutics ($JANX) has reintroduced a TROP2-targeting asset into its pipeline and continues to develop its CD28 program, while data from its JANX007 and JANX008 clinical trials remain pending. The company’s novel TROP2 masked-T cell engager (TCE), previously listed but subsequently removed from its website, is gaining attention as one of the first TCEs to demonstrate strong activity in solid tumors. Investors have inquired about the durability and efficacy of JANX007 and JANX008, but the company has yet to provide detailed updates. Additionally, Janux is working on reducing immune-related side effects such as immune response syndrome (IRS) and T cell exhaustion in its CD19-ARM program. The company holds over $1 billion in cash, providing financial support for ongoing and upcoming clinical milestones, including interim pivotal data for JANX007 and phase 1b data for JANX008. Bank of America has maintained a Buy rating on Janux with a price target of $64, citing the need for clinical validation to bolster investor confidence. Meanwhile, other biotech stocks like Exelixis ($EXEL) are showing promising breakout patterns in the high-growth momentum sector.